Join our daily newsletter At The Bell to receive exclusive market insights
Optiscan (ASX: OIL) has unveiled InVue, a new microscopic medical imaging device, designed to enable precision surgery by putting real-time digital pathology access directly into the hands of surgeons.
Designed and manufactured in Melbourne in partnership with Australian industrial design firm, Design + Industry, Optiscan said the device is designed to give surgeons immediate pathology insights in the operating theatre to enable on the spot decision making, treatment adjustments and precision surgery.
Historically, pathology has been conducted within dedicated laboratories using analogue approaches separated from the operating theatre. This has proven to be time consuming, requiring multiple procedures and only delivered results after significant time delays.
The InVue™ device has been designed for ease of use in various clinical settings such as cancer diagnosis and treatment and will deliver real-time microscopic imaging and pathology detail to surgeons.
Optiscan hopes this will improve the accuracy of their diagnoses and reduce the need for multiple diagnostic procedures and repeat surgeries.
Optiscan was up 16% trading at 14 cents.
